Ventas Inc
$ 92.53
1.85%
05 Aug - close price
- Market Cap 47,462,928,000 USD
- Current Price $ 92.53
- High / Low $ 92.97 / 90.18
- Stock P/E 168.24
- Book Value 28.56
- EPS 0.55
- Next Earning Report -
- Dividend Per Share $2.00
- Dividend Yield 2.2 %
- Next Dividend Date -
- ROA 0.02 %
- ROE 0.02 %
- 52 Week High 101.60
- 52 Week Low 64.72
About
Ventas, Inc. is a real estate investment trust specializing in the ownership and management of health care facilities in the United States, Canada and the United Kingdom.
Analyst Target Price
$100.73
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-07-29 | 2026-04-27 | 2026-02-05 | 2025-10-29 | 2025-07-30 | 2025-04-30 | 2025-02-12 | 2024-10-30 | 2024-08-01 | 2024-05-01 | 2024-02-14 | 2023-11-02 |
| Reported EPS | 0.97 | 0.1 | 0.13 | 0.12 | 0.15 | 0.1 | 0.13 | 0.05 | 0.02 | -0.03 | -0.3 | -0.18 |
| Estimated EPS | 0.96 | 0.1 | 0.09 | 0.05 | 0.14 | 0.07 | 0.05 | -0.02 | 0.01 | -0.38 | -0.17 | -0.01 |
| Surprise | 0.01 | 0 | 0.04 | 0.07 | 0.01 | 0.03 | 0.08 | 0.07 | 0.01 | 0.35 | -0.13 | -0.17 |
| Surprise Percentage | 1.0417% | 0% | 44.4444% | 140% | 7.1429% | 42.8571% | 160% | 350% | 100% | 92.1053% | -76.4706% | -1700% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 | Apr 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-07-16 | 2026-04-16 | 2026-01-15 | 2025-10-16 | 2025-07-17 | 2025-04-17 | 2025-01-16 | 2024-10-17 | 2024-07-18 | 2024-04-18 |
| Amount | $0.52 | $0.52 | $0.48 | $0.48 | $0.48 | $0.48 | $0.45 | $0.45 | $0.45 | $0.45 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: VTR
2026-08-05 16:04:57
Argus Research has increased its price target for Ventas (VTR) to $98 from $92.
2026-08-04 23:13:09
Ventas has filed a Form 3 for Andy Wattula, EVP OM&R-Ventas and president and CEO of LHS, effective August 1st. This filing indicates Wattula as an initial beneficial owner. The news brief was generated by AI using information from Ventas Inc.'s original content published via EDGAR.
2026-08-04 21:39:25
Ventas, Inc. (NYSE: VTR) executive Andy Wattula was granted two equity compensation awards of restricted stock units (RSUs) on August 1, 2026. The awards consist of 10,694 units vesting in 2027, 2028, and 2029, and 4,314 units vesting in three equal annual installments, all under the 2022 Incentive Plan at a reference price of $93.51 per share. These grants are compensation awards, not open-market purchases.
2026-08-04 21:09:47
Ventas, Inc. reported an initial insider ownership statement (Form 3) for executive Andy Wattula, identifying him as an officer with the title "EVP OM&R-Ventas/Pres&CEO-LHS." The report indicates he is not a director or 10% owner and lists no insider transactions or derivative holdings. The filing also notes "Exhibit 24 - Power of Attorney."
2026-08-04 15:07:10
Alexandria Real Estate Equities (ARE) reported mixed Q2 2026 results with weaker revenue and a net loss, but improved year-to-date profitability. The company is also making progress on the MAP-D depression research initiative, reinforcing its position in the life science sector. While short-term challenges like high interest rates and soft tenant demand persist, the MAP-D initiative could influence future leasing and tenant mix, potentially stabilizing net
2026-08-04 10:53:20
Citigroup has increased its price target for Ventas (NYSE: VTR) to $110 from $100, while reaffirming its Buy rating on the stock. This adjustment reflects Citigroup's updated outlook on the specialized REIT, which focuses on healthcare and medical-residential facilities. The article also notes similar price target adjustments from other firms like Evercore ISI, BMO Capital, and BNP Paribas, indicating a generally positive sentiment from analysts towards Ventas.
